|
Name |
Luteolin
|
Molecular Formula | C15H10O6 | |
IUPAC Name* |
2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one
|
|
SMILES |
C1=CC(=C(C=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O)O
|
|
InChI |
InChI=1S/C15H10O6/c16-8-4-11(19)15-12(20)6-13(21-14(15)5-8)7-1-2-9(17)10(18)3-7/h1-6,16-19H
|
|
InChIKey |
IQPNAANSBPBGFQ-UHFFFAOYSA-N
|
|
Synonyms |
luteolin; 491-70-3; Digitoflavone; Luteolol; 3',4',5,7-Tetrahydroxyflavone; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one; Flacitran; Luteoline; Salifazide; Weld Lake; Yama kariyasu; Cyanidenon 1470; Bismite; 5,7,3',4'-Tetrahydroxyflavone; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one; C.I. Natural Yellow 2; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-benzopyrone; Daphneflavonol; Flavopurpol; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-; Cyanidenon-1470; BRN 0292084; MFCD00017309; KUX1ZNC9J2; CHEMBL151; FLAVONE, 3',4',5,7-TETRAHYDROXY-; CHEBI:15864; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-1-benzopyran-4-one; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-chromenone; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-chromen-4-one; 1318-21-4; SMR000326896; 7-Tetrahydroxyflavone; CCRIS 3790; SR-01000779333; EINECS 207-741-0; UNII-KUX1ZNC9J2; Argemexitin; C.I. 75590; 4dew; 4dgn; 4hkn; Luteolin,(S); LU2; Prestwick_122; LUTEOLIN [INCI]; LUTEOLIN [MI]; Prestwick0_000870; Prestwick1_000870; Prestwick2_000870; Prestwick3_000870; LUTEOLIN [WHO-DD]; BIDD:PXR0059; Lopac0_000660; Oprea1_849964; SCHEMBL20426; BSPBio_000919; Luteolin, analytical standard; MLS000697655; MLS000860038; MLS002154043; MLS006011917; BIDD:ER0122; SPBio_002840; BDBM7459; BPBio1_001011; GTPL5215; MEGxp0_000143; DTXSID4074988; ACon1_000223; cid_5280445; HMS1570N21; HMS2097N21; HMS2220C06; HMS3356L02; HMS3561N09; HMS3649N21; HMS3656A05; HMS3714N21; Luteolin, >=99.0% (TLC); BCP03511; HY-N0162; TNP00073; Luteolin, >=98% (TLC), powder; BBL027837; LMPK12110006; s2320; STK801923; ZINC18185774; AKOS002140588; AC-1125; BCP9000865; CCG-208309; CS-4611; DB15584; KS-5202; Luteolin 100 microg/mL in Acetonitrile; SMP2_000042; NCGC00016467-01; NCGC00016467-02; NCGC00016467-03; NCGC00016467-04; NCGC00016467-05; NCGC00016467-06; NCGC00016467-07; NCGC00016467-08; NCGC00016467-21; NCGC00142375-01; NCGC00142375-02; NCGC00142375-03; NCGC00179375-01; NCGC00179375-02; CAS-491-70-3; SY030155; BCP0726000198; FT-0600053; SW196433-3; T2682; 91L703; C01514; L 9283; S00110; EN300-1659559; A827664; Luteolin, primary pharmaceutical reference standard; Q415011; Q-100551; SR-01000779333-4; SR-01000779333-5; SR-01000779333-7; BRD-K05236810-001-05-9; 23A002A4-B47B-46CD-848C-65042EACF3FF; NCGC00142375-01,NCGC00142375-02; Z1741977179; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4H-benzopyrone-4-one; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one #; 4H-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-
|
|
CAS | 491-70-3 | |
PubChem CID | 5280445 | |
ChEMBL ID | CHEMBL151 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 286.24 | ALogp: | 1.4 |
HBD: | 4 | HBA: | 6 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 107.0 | Aromatic Rings: | 3 |
Heavy Atoms: | 21 | QED Weighted: | 0.512 |
Caco-2 Permeability: | -5.028 | MDCK Permeability: | 0.00001000 |
Pgp-inhibitor: | 0.004 | Pgp-substrate: | 0.274 |
Human Intestinal Absorption (HIA): | 0.047 | 20% Bioavailability (F20%): | 0.998 |
30% Bioavailability (F30%): | 1 |
Blood-Brain-Barrier Penetration (BBB): | 0.009 | Plasma Protein Binding (PPB): | 95.44% |
Volume Distribution (VD): | 0.533 | Fu: | 5.98% |
CYP1A2-inhibitor: | 0.981 | CYP1A2-substrate: | 0.154 |
CYP2C19-inhibitor: | 0.124 | CYP2C19-substrate: | 0.046 |
CYP2C9-inhibitor: | 0.576 | CYP2C9-substrate: | 0.842 |
CYP2D6-inhibitor: | 0.568 | CYP2D6-substrate: | 0.559 |
CYP3A4-inhibitor: | 0.549 | CYP3A4-substrate: | 0.092 |
Clearance (CL): | 8.146 | Half-life (T1/2): | 0.898 |
hERG Blockers: | 0.064 | Human Hepatotoxicity (H-HT): | 0.084 |
Drug-inuced Liver Injury (DILI): | 0.905 | AMES Toxicity: | 0.536 |
Rat Oral Acute Toxicity: | 0.046 | Maximum Recommended Daily Dose: | 0.741 |
Skin Sensitization: | 0.946 | Carcinogencity: | 0.095 |
Eye Corrosion: | 0.009 | Eye Irritation: | 0.944 |
Respiratory Toxicity: | 0.22 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001533 | 0.701 | D04AIT | 1.000 | ||||
ENC001529 | 0.686 | D0K8KX | 0.686 | ||||
ENC001548 | 0.568 | D06GCK | 0.460 | ||||
ENC001751 | 0.550 | D07MGA | 0.368 | ||||
ENC004389 | 0.549 | D0U3YB | 0.341 | ||||
ENC001573 | 0.545 | D0TC7C | 0.312 | ||||
ENC001575 | 0.495 | D0AZ8C | 0.311 | ||||
ENC005391 | 0.494 | D08LFZ | 0.289 | ||||
ENC002024 | 0.493 | D00KRE | 0.283 | ||||
ENC002018 | 0.493 | D06KYN | 0.281 |